Compare Marriott International Inc (MAR) vs Summit Therapeutics Inc (SMMT) Price & Performance

Marriott International (MAR) trades at $363.49, up 1.96% today, showing strong momentum near resistance at $364. The stock maintains a bullish technical outlook with positive moving averages and ADX signals. Fundamentally, revenue grew to $26.19B in 2025 with a 9.62% net margin, though valuation metrics appear elevated with a P/E of 37.38. Recent earnings beat expectations in Q1 and Q2 2026, while analysts maintain a consensus price target of $386.71 with 44% buy ratings.

Outlook remains positive driven by travel demand recovery and strategic partnerships, but risks include rising debt levels (debt-to-asset ratio at 58.83% in 2025) and economic sensitivity. The stock offers moderate upside to analyst targets with institutional confidence, though high valuation requires sustained earnings growth to justify current levels.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.